MJRuecke

[MJRuecke @MJRuecke]

@SouthernDrive21 Another stall tactic!

[Kelly @Kelly712717541]

$nwbo

[PK_Fund @PK_Fund]

$NWBO
In short, the roadmap is now unmistakably clear:
Approval triggers a flood of long‑restricted data, the stock uplists within 2–3 months as the company transforms into a true immunotherapy platform leader, and the endgame becomes a major pharma partnership or a full buyout. NWBO shifts from an overlooked OTC biotech to one of the most strategically valuable assets in oncology!

-> Approval
-> News avalanche
->Uplisting after 2–3 months
-> NWBO becomes a platform icon
-> Major BP deal or full buyout

Let's go...NWBO

[SemperFITrader @SouthernDrive21]

$NWBO Expect a PR after the Dr. Marnix Bosch talk on PSM (propensity score matching) data analysis between 6:00-8:00am EST on Friday July 3rd assuming the data is positive as we investors assume it is. This comes after my discussion with GZ today on such matters. Maybe us Investors can have more to celebrate on 4th of July on top of the 250 Year Celebration anniversary of the signing of the Declaration of Independence!

[NWBOstacks @EatYerShorts]

$NWBO sure is acting like a company anticipating a cash infusion in the near future.

• Building dedicated leukapheresis clinic

• Acquired Advent BioServices + consolidating UK mfg at Sawston

• Started construction on new Grade C manufacturing suite

• In-licensed Kalinski DC tech portfolio for platform expansion

Are they anticipating settlements from the MMs, and/or do they see this financing dynamo putting together some wins? 👇

[NWBOstacks @EatYerShorts]

$NWBO Joint Discovery Letter just dropped (63 pages)

Light on agreements. Heavy on arguments.

Here's both sides' stances straight from the docs:

NWBO's position:

• Produced 61k+ docs total (just added 1k+ on May 29), fixed most search terms, and keep compromising.

• Brokers produced pathetic 823 total: Citadel 257, others scraping scraps. Zero comms, barely any non-public docs, no algos.

• Demanding full productions + complete privilege logs by June 26, real trading data, spoof analyses, proper custodians, and broader relevant periods.

• MM's searches are weak, unilateral, and laughably narrow.

MM's position:

• NWBO's demands are overbroad, late, burdensome, and fishing. We've given enough on spoof episodes and trading data.

• NWBO's dragging with delays, zero analyses produced, and unrealistic asks.

• Our productions are complete and tailored per court rulings. No need for more.
----

This beef is nuclear on hit counts, time windows, RFPs, and stonewalling.

NWBO threatens Motion to Compel.

Magistrate Stein's about to drop the gavel.

[MJRuecke @MJRuecke]

@acathleen5 @BarronTNews_ If they don’t want to represent the country they could always renounce citizenship and move to the country they feel is greater than the Freedom afforded them in the USA!

[Peter Davis @peter_brit]

#dcvax $nwbo #gbm

Gemini AI Analysis of MHRA Regulatory changes

For Northwest Biotherapeutics (NW Bio) and its DCVax platform, this update has specific implications for its current regulatory path and future commercial status in the UK.

Summary: On 9 February 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) issued updated information for Marketing Authorisation Holders (MAHs) about the implications of recent changes to CIR 520/2012 — the EU pharmacovigilance implementing regulation — which come into force on 12 February 2026. While UK medicines are regulated under the Human Medicines Regulations 2012, there are ongoing overlaps with EU pharmacovigilance requirements for some products, particularly Category 2 medicines that are authorised both in the UK and the EU.

The update you referenced regarding CIR 520/2012 (the EU Commission Implementing Regulation on pharmacovigilance) is a technical regulatory change by the UK’s MHRA to manage the "decoupling" of UK and EU pharmacovigilance (PV) rules.

For Northwest Biotherapeutics (NW Bio) and its DCVax platform, this update has specific implications for its current regulatory path and future commercial status in the UK.

1. What is the CIR 520/2012 Update?
As of February 12, 2026, the UK and EU rules for monitoring drug safety (pharmacovigilance) have diverged.

Category 1 medicines (purely UK-authorized products) now follow UK-specific rules (HMR Schedule 12A).

Category 2 medicines (products with licenses in both the UK and EU, or those that fall under the Windsor Framework's "Category 2") must follow the updated EU CIR 520/2012 rules.

The MHRA issued this guidance to tell companies which "rulebook" to follow to avoid double-reporting or compliance gaps.

2. Effect on DCVax’s "Current Status" (The MAA Process)
NW Bio submitted its Marketing Authorization Application (MAA) for DCVax-L to the MHRA in December 2023.

Compliance Readiness: Because DCVax-L is being reviewed as a "New Active Substance" and an "Advanced Therapy Medicinal Product" (ATMP), it falls under Category 1 (UK-wide authorization) under the Windsor Framework.

No Delay to Approval: This update is about post-approval safety monitoring. It does not change the criteria for "efficacy" or "safety" required for the MHRA to grant approval. It simply defines the administrative workflow NW Bio must use to report side effects once the drug is on the market.

Operational Burden: NW Bio has already established a manufacturing and regulatory footprint in the UK (via its Sawston facility). They will likely need to ensure their Pharmacovigilance System Master File (PSMF) is updated to reflect whether they are following the UK-specific Schedule 12A or the EU CIR 520/2012 (if they seek EU approval simultaneously).

3. Effect on "Potential Future Status"
International Alignment: If NW Bio intends to use the UK approval as a "springboard" for EU or global markets, the divergence in CIR 520/2012 means they will have to manage two slightly different sets of data-reporting standards. For a small biotech, this increases the administrative overhead for their "Future Status" as a global commercial entity.

Expansion of the Platform: For future iterations of the platform (e.g., DCVax-Direct or other solid tumors), the "Category 1" designation in the UK remains the likely path. The MHRA’s goal with these updates is to provide a "swift approval" environment. By clarifying these rules now, the MHRA is attempting to make the UK a more predictable environment for innovative therapies like DCVax.

Summary for DCVax
Approval Timeline: Not affected. This is a safety-reporting update, not an approval hurdle.

Manufacturing (Sawston): Not affected. This concerns data reporting, not physical production.

Regulatory Work: Slight increase. NW Bio's regulatory team must ensure their safety monitoring software and protocols align with the MHRA's new decision-making flowchart (distinguishing between Category 1 and Category 2 requirements).

In short: This is a procedural adjustment for how the company handles safety data after they get the "green light," rather than a threat to the technology or the platform's viability. - Gemini AI Analysis

https://t.co/qagCUHPnAw

[Gregory Zivic, MD @metacollectiveG]

$NWBO while investors wring their hands in frustration and fall for short’s tricks real work goes on in the important places. Follow science not charts. https://t.co/8p1VGVjg9L

[🇩🇰 The Danish Dude 🇬🇱 @FlemmingBruce]

$NWBO

Post 1/2

Thanks to @ATLnsider for this research which I will try to dig into.

https://t.co/cEnWPhDGcQ

The Hidden "Cure" Trade in $NWBO

Most investors are watching Northwest Biotherapeutics for one thing:

the DCVax-L approval for brain cancer (GBM). While that is huge, it’s missing a much bigger picture that has quietly developed in the background.

$NWBO has secured the rights to a next-generation technology that is currently curing "incurable" Stage 4 breast cancer in human trials.

This isn't a mouse study. It’s happening right now in patients.

In June 2024, NWBO announced an exclusive worldwide license with Roswell Park Comprehensive Cancer Center. This deal gave them control of the "Alpha-DC1" platform developed by Dr. Pawel Kalinski and Dr. Brian Czerniecki.

Why does this matter? Because a recent patient case at Moffitt Cancer Center—using this exact method - just provided what looks like a "functional cure" for metastatic disease.

If you are only valuing $NWBO on GBM, you are getting a free call option on a multi-billion dollar breast cancer franchise.

Here is the breakdown of the "Dallas Carroll" signal and why it changes the investment thesis.

The "Dallas Carroll" Signal - Proof of Concept

To understand the value of the asset NWBO bought, look at the patient data coming out of Moffitt Cancer Center.
Dallas Carroll was a young mother diagnosed with Stage 4 HER2-positive breast cancer. It had spread (metastasized) to her liver and bones. In standard oncology, this is a terminal diagnosis.

You don't cure it; you just try to extend life by a few years with chemo.

She enrolled in a trial led by Dr. Brian Czerniecki - Dr. Kalinski’s long-time partner and co-inventor of the tech NWBO licensed.

The treatment was different. Instead of just injecting a vaccine into the skin, they injected these "Alpha-DC1" dendritic cells directly into her breast tumor.

The result?

The immune system woke up. It didn't just attack the breast tumor; it hunted down the cancer in her liver and bones and cleared them out.

18 months later, she is cancer-free (No Evidence of Disease). Surgeons were able to remove the primary mass and found the cancer was dead.

This is called the "Abscopal Effect" - treating one spot to cure the whole body. This is the Holy Grail of cancer treatment, and NWBO now owns the rights to the platform that achieved it.

How It Works

Why did this work when other vaccines failed?

Most solid tumors (like breast cancer) are "Cold." They build a wall around themselves that immune cells can't penetrate. You can have plenty of killer T-cells in your blood, but if they can't get inside the tumor, they are useless.

The technology NWBO licensed (the Kalinski/Czerniecki IP) solves this two ways:

1. The GPS Signal (Chemokines):

The "Alpha-DC1" cells are engineered to release massive amounts of chemical signals. Think of this like dropping a GPS pin inside the tumor that screams "HERE!" to the immune system. It physically pulls killer T-cells out of the blood and into the tumor.

2. The Training:

Once the T-cells arrive, the vaccine trains them to recognize the specific "scent" of the cancer.

Because they injected it directly into the tumor, the immune system learned to recognize the cancer at the source. Those trained cells then traveled through the blood to scrub the liver and bones clean.

This effectively turns the patient's own tumor into its own vaccine factory.

[MJRuecke @MJRuecke]

@TheSports_Shift False the run Defense is horrible been a fan since 68 they won’t be able to stop MacCaffery this weekend. I’m hoping they figure it out and this isn’t true, but watching all year they haven’t been any signs of stopping the run. Bear Down!!

[MJRuecke @MJRuecke]

@flygawdblaxk 1968 you don’t know the pain but we did have 85!

[MJRuecke @MJRuecke]

@ChiBearsHistory 12775

[Mo @c14aka]

💥 One company under 25¢ is closer to cracking brain cancer than Big Pharma.

$NWBO → DCVax-L showed survival gains no drug ever has.

This isn’t just biotech… it’s impact + asymmetric wealth.

Early holders will be remembered. 🚀
#NWBO #cancercure
@TateTheTalisman @Cobratate

[MJRuecke @MJRuecke]

@andyd420 @NYRangers Advertising for many years

[ATLnsider @ATLnsider]

$NWBO is now a fully vertically integrated biotech / pharmaceutical company with manufacturing, research & development (R&D), management & marketing all under 1 umbrella. The next domino that will fall soon is MHRA approval of DCVax. With its #DCVax tissue / tumor agnostic dendritic cell cancer vaccine technology platform & extensive global patent IP portfolio, how much is that worth. Here’s a clue:

[Richard Fairgrieve @RichFairgrieve]

2025 Version: Can Tiny $NWBO Survive Against the Big Guys? My money says yes. And it's not just BP but Wall St. as well. Lots of people want this company to fail.

[MJRuecke @MJRuecke]

@Hspooner665 Nailed it! Time is running out for the shorts!

[Jose Garza @JPGarza84]

if approved for all solid tumors, is not just a single therapy—it’s a platform that:
is personalized,
applies to virtually every cancer indication,
has broad combination potential with checkpoint inhibitors and possibly mRNA vac,
and includes curative metastatic use cases.